Return to Today's science sparks archives

2021-04-01

Figure 3: Blood counts (cells/μl) of CD27+ IgD− memory B cells (A) and CD16hi NK cells (B) in patients, stratified by relapse and maraviroc treatment.

Figure 3: Blood counts (cells/μl) of CD27+ IgD− memory B cells (A) and CD16hi NK cells (B) in patients, stratified by relapse and maraviroc treatment.
  • Pasin C, Moy RH, Reshef R, Yates AJ

  • Sci Rep. 2021 Feb 5;11(1):3230. doi: 10.1038/s41598-021-82562-0.
Open Access button

2021-04-02

Figure 2. Adjusted total reimbursements within 1 year of undergoing allo-HCT for patients with and without virus-associated HC, stratified by GVHD.

Figure 2. Adjusted total reimbursements within 1 year of undergoing allo-HCT for patients with and without virus-associated HC, stratified by GVHD.
  • McGuirk J, Divine C, Moon SH, Chandak A, Zhang Z, Papanicolaou GA

  • Transplant Cell Ther. 2021 Feb 26. pii: S2666-6367(21)00708-9. doi: 10.1016/j.jtct.2021.02.021.

2021-04-05

Graphical Abstract

Graphical Abstract
  • Jo A, Li S, Shin JW, Zhao X, Cho Y

  • J Mol Biol. 2021 Mar 4;433(9):166910. doi: 10.1016/j.jmb.2021.166910.

2021-04-07

Figure 5. Downstream effectors of human airway basal cell EV–mediated survival of HUVECs.

Figure 5. Downstream effectors of human airway basal cell EV–mediated survival of HUVECs.
  • Saxena A, Walters MS, Shieh JH, Shen LB, Gomi K, Downey RJ, Crystal RG, Moore MAS

  • Sci Rep. 2021 Mar 17;11(1):6104. doi: 10.1038/s41598-021-85534-6.
Open Access button

2021-04-08

Fig. 1. Distribution of Added Path Length (APL) across volumes of interest, as represented by kernel density plots.

Fig. 1. Distribution of Added Path Length (APL) across volumes of interest, as represented by kernel density plots.
  • Cha E, Elguindi S, Onochie I, Gorovets D, Deasy JO, Zelefsky M, Gillespie EF

  • Radiother Oncol. 2021 Mar 3;159:1-7. doi: 10.1016/j.radonc.2021.02.040.

2021-04-09

Fig 1. Information needed to determine harms of overused services.

Fig 1. Information needed to determine harms of overused services.
  • Brownlee SM, Korenstein D

  • BMJ. 2021 Mar 23;372:n117. doi: 10.1136/bmj.n117.

2021-04-12

Fig 1. Smart-ORF cell-free system for imaging both uORF and mORF translation on single mRNA molecules.

Fig 1. Smart-ORF cell-free system for imaging both uORF and mORF translation on single mRNA molecules.
  • Gaba A, Wang H, Fortune T, Qu X

  • Nucleic Acids Res. 2021 Mar 18;49(5):e26. doi: 10.1093/nar/gkaa1185.
Open Access button

2021-04-13

Fig 2. Penicillin Allergy Testing Procedure

Fig 2. Penicillin Allergy Testing Procedure
  • Morjaria S, Inumerables F, Patel D, Cohen N, Seo S, Posthumus S, Martin SC, Kaltsas A, Lee S, Boucher N, Fischer-Cartlidge E

  • Clin J Oncol Nurs. 2021 Apr 1;25(2):143-150. doi: 10.1188/21.CJON.143-150.

2021-04-14

Figure 2. Human and mouse memory NK cell traits.

Figure 2. Human and mouse memory NK cell traits.
  • Sheppard S, Sun JC

  • J Exp Med. 2021 Apr 5;218(4). pii: 211913. doi: 10.1084/jem.20201731.

2021-04-15

Figure 1. Timeline of the strategic mitigation planning for the management of patients during the COVID-19 pandemic, and data on the Cumulative incidence of COVID-19 positivity in MSK pediatric patients, MSK caregivers, and the pediatric population in NYC.

Figure 1. Timeline of the strategic mitigation planning for the management of patients during the COVID-19 pandemic, and data on the Cumulative incidence of COVID-19 positivity in MSK pediatric patients, MSK caregivers, and the pediatric population in NYC.
  • Szenes V, Bright R, Diotallevi D, Melendez G, Martinez C, Zakak N, Killinger J, Gilheeney S, Roberts SS, Kamboj M, Bender JG, Kung AL, Boulad F

  • J Pediatr Oncol Nurs. 2021 Mar 8:1043454221992301. doi: 10.1177/1043454221992301.

2021-04-16

Fig. 1: Mutational profiles and copy number alterations of cervical mesonephric carcinomas and mesonephric-like carcinomas of the ovary and endometrium.

Fig. 1: Mutational profiles and copy number alterations of cervical mesonephric carcinomas and mesonephric-like carcinomas of the ovary and endometrium.
  • da Silva EM, Fix DJ, Sebastiao APM, Selenica P, Ferrando L, Kim SH, Stylianou A, Da Cruz Paula A, Pareja F, Smith ES, Zehir A, Konner JA, Cadoo K, Reis-Filho JS, Abu-Rustum NR, Mueller JJ, Weigelt B, Park KJ

  • Mod Pathol. 2021 Mar 26. pii: 10.1038/s41379-021-00799-6. doi: 10.1038/s41379-021-00799-6.

2021-04-19

Fig. 2 Photomicrographs for which participants were asked to provide PNI ratings.

Fig. 2 Photomicrographs for which participants were asked to provide PNI ratings.
  • Yan F, Cheng YL, Katabi N, Nguyen SA, Chen HS, Morgan P, Zhang K, Chi AC

  • Head Neck Pathol. 2021 Mar 31. pii: 10.1007/s12105-021-01321-9. doi: 10.1007/s12105-021-01321-9.

2021-04-20

Fig. 1 a Distribution of factors for not recommending cytoreductive nephrectomy.

Fig. 1 a Distribution of factors for not recommending cytoreductive nephrectomy.
  • Silagy AW, Attalla K, Dinatale RG, Weiss KL, Weng S, Mano R, Iosepovici S, Marcon J, Reznik E, Kotecha RR, Motzer RJ, Voss MH, Coleman JA, Hakimi AA, Russo P

  • World J Urol. 2021 Mar 29. pii: 10.1007/s00345-021-03650-4. doi: 10.1007/s00345-021-03650-4.

2021-04-21

FIGURE 2: Landscape of solid tumor CAR trials.

FIGURE 2: Landscape of solid tumor CAR trials.
  • Schoenfeld AJ, O'Cearbhaill RE

  • Cancer J. 2021 Mar-Apr 01;27(2):134-142. doi: 10.1097/PPO.0000000000000516.
Open Access button

2021-04-22

Figure 5. Genome wide changes in H3K27me3 parallel changes identified at the HoxA9 locus.

Figure 5. Genome wide changes in H3K27me3 parallel changes identified at the HoxA9 locus.
  • Heimbruch KE, Fisher JB, Stelloh CT, Phillips E, Reimer MH Jr, Wargolet AJ, Meyer AE, Pulakanti K, Viny AD, Loppnow JJ, Levine RL, Pulikkan JA, Zhu N, Rao S

  • Sci Rep. 2021 Mar 31;11(1):7288. doi: 10.1038/s41598-021-86646-9.
Open Access button

2021-04-23

Fig 1. Progression-free and Overall Survival in the Intention-to-Treat Population.

Fig 1. Progression-free and Overall Survival in the Intention-to-Treat Population.
  • Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juarez VM, Hsieh JJ, Basso U, Shah AY, Suarez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Zolnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ

  • N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.

2021-04-26

Fig. 2. Representative examples.

Fig. 2. Representative examples.
  • Chan AT, Dinsfriend W, Kim J, Yum B, Sultana R, Klebanoff CA, Plodkowski A, Perez Johnston R, Ginsberg MS, Liu J, Kim RJ, Steingart R, Weinsaft JW

  • J Cardiovasc Magn Reson. 2021 Apr 5;23(1):42. doi: 10.1186/s12968-021-00727-2.
Open Access button

2021-04-27

Figure 1. Estimated probabilities of developing metastatic disease (A) and prostate cancer specific survival (B) after definitive treatment of localized prostate cancer stratified by MRI category.

Figure 1. Estimated probabilities of developing metastatic disease (A) and prostate cancer specific survival (B) after definitive treatment of localized prostate cancer stratified by MRI category.
  • Wibmer AG, Chaim J, Lakhman Y, Lefkowitz RA, Nincevic J, Nikolovski I, Sala E, Gonen M, Carlsson SV, Fine SW, Zelefsky MJ, Scardino P, Hricak H, Vargas HA

  • J Urol. 2021 Apr;205(4):1055-1062. doi: 10.1097/JU.0000000000001474. Epub 2020 Nov 18.

2021-04-28

Graphical abstract.

Graphical abstract.
  • Bojmar L, Kim HS, Tobias GC, Pelissier Vatter FA, Lucotti S, Gyan KE, Kenific CM, Wan Z, Kim KA, Kim D, Hernandez J, Pascual V, Heaton TE, La Quaglia MP, Kelsen D, Trippett TM, Jones DR, Jarnagin WR, Matei IR, Zhang H, Hoshino A, Lyden D

  • STAR Protoc. 2020 Dec 22;2(1):100225. doi: 10.1016/j.xpro.2020.100225. eCollection 2021 Mar 19.

2021-04-29

Fig. 1. Arsenic usage and temporal association with herpes zoster infection.

Fig. 1. Arsenic usage and temporal association with herpes zoster infection.
  • Glass JL, Derkach A, Hilden P, King A, Seo SK, Ahr K, Kishtagari A, Levine RL, Tallman MS, Douer D

  • Leuk Res. 2021 Mar 31;106:106569. doi: 10.1016/j.leukres.2021.106569.

2021-04-30

Graphical Abstract.

Graphical Abstract.
  • Wang Y, Song M, Liu M, Zhang G, Zhang X, Li MO, Ma X, Zhang JJ, Huang XY

  • Cell Rep. 2021 Apr 6;35(1):108948. doi: 10.1016/j.celrep.2021.108948.
Open Access button

2021-05-03

Fig 1. Burnout versus burnout syndrome. High risk for burnout is classified as reaching threshold levels of either emotional exhaustion and/or depersonalization

Fig 1. Burnout versus burnout syndrome. High risk for burnout is classified as reaching threshold levels of either emotional exhaustion and/or depersonalization
  • Afonso AM, Cadwell JB, Staffa SJ, Zurakowski D, Vinson AE

  • Anesthesiology. 2021 May 1;134(5):683-696. doi: 10.1097/ALN.0000000000003722.

2021-05-04

Graphical abstract.

Graphical abstract.
  • Szanto CL, Cornel AM, Tamminga SM, Delemarre EM, de Koning CCH, van den Beemt DAMH, Dunnebach E, Tas ML, Dierselhuis MP, Tytgat LGAM, van Noesel MM, Kraal KCJM, Boelens JJ, Huitema ADR, Nierkens S

  • Cancers (Basel). 2021 Apr 26;13(9). pii: cancers13092096. doi: 10.3390/cancers13092096.
Open Access button

2021-05-05

Fig 1. KRAS mutation subtypes and baseline pathologic and molecular characteristics.

Fig 1. KRAS mutation subtypes and baseline pathologic and molecular characteristics.
  • Arbour KC, Rizvi H, Plodkowski AJ, Hellmann MD, Knezevic A, Heller G, Yu HA, Ladanyi M, Kris MG, Arcila ME, Rudin CM, Lito P, Riely GJ

  • Clin Cancer Res. 2021 Apr 15;27(8):2209-2215. doi: 10.1158/1078-0432.CCR-20-4023. Epub 2021 Feb 8.

2021-05-06

Fig. 2: Best RECIST response, PTEN, and broader mutation profiling in patients with PTEN-mutant ER+ MBC treated with capivasertib and fulvestrant.

Fig. 2: Best RECIST response, PTEN, and broader mutation profiling in patients with PTEN-mutant ER+ MBC treated with capivasertib and fulvestrant.
  • Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S

  • NPJ Breast Cancer. 2021 Apr 16;7(1):44. doi: 10.1038/s41523-021-00251-7.
Open Access button

2021-05-07

Figure 2. Subgroup analysis of 90-day mortality and survival after ICU admission

Figure 2. Subgroup analysis of 90-day mortality and survival after ICU admission
  • Azoulay E, Castro P, Maamar A, Metaxa V, de Moraes AG, Voigt L, Wallet F, Klouche K, Picard M, Moreau AS, Van De Louw A, Seguin A, Mokart D, Chawla S, Leroy J, Boll B, Issa N, Levy B, Hemelaar P, Fernandez S, Munshi L, Bauer P, Schellongowski P, Joannidis M, Moreno-Gonzalez G, Galstian G, Darmon M, Valade S

  • Lancet Haematol. 2021 May;8(5):e355-e364. doi: 10.1016/S2352-3026(21)00060-0.

2021-05-10

Figure 1. SNPs in high LD of the index SNP (rs35418111) in Asians (rs8134832, rs57385578, rs8126917, and rs2078203) and Europeans (rs57385578) were prioritized using HaploReg v4.1 annotation.

Figure 1. SNPs in high LD of the index SNP (rs35418111) in Asians (rs8134832, rs57385578, rs8126917, and rs2078203) and Europeans (rs57385578) were prioritized using HaploReg v4.1 annotation.
  • Shidal C, Shu X, Wu J, Wang J, Huang S, Long J, Bauer JA, Ping J, Guo X, Zheng W, Shu XO, Cai Q

  • Cancers (Basel). 2021 Apr 23;13(9). pii: cancers13092037. doi: 10.3390/cancers13092037.
Open Access button

2021-05-11

QSER1 safeguards DNA methylation valleys from de novo methylation.

QSER1 safeguards DNA methylation valleys from de novo methylation.
  • Dixon G, Pan H, Yang D, Rosen BP, Jashari T, Verma N, Pulecio J, Caspi I, Lee K, Stransky S, Glezer A, Liu C, Rivas M, Kumar R, Lan Y, Torregroza I, He C, Sidoli S, Evans T, Elemento O, Huangfu D

  • Science. 2021 Apr 9;372(6538). pii: 372/6538/eabd0875. doi: 10.1126/science.abd0875.

2021-05-12

Fig. 2: Common primary cancers metastasizing to the liver.

Fig. 2: Common primary cancers metastasizing to the liver.
  • Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D'Angelica MI, Endo I, Parks RW, Doyle M, de Santibanes E, Pawlik TM

  • Nat Rev Dis Primers. 2021 Apr 15;7(1):27. doi: 10.1038/s41572-021-00261-6.

2021-05-13

Figure 1 Dose‐normalized plasma galunisertib concentrations at steady state (following treatment on day 14) with monotherapy (Part A) and combination with ramucirumab (Part D).

Figure 1 Dose‐normalized plasma galunisertib concentrations at steady state (following treatment on day 14) with monotherapy (Part A) and combination with ramucirumab (Part D).
  • Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Benhadji KA, Kelley RK, Abou-Alfa GK

  • Cancer Med. 2021 Apr 2. doi: 10.1002/cam4.3880.
Open Access button

2021-05-14

Fig 1. Waterfall plots of best response to entrectinib in patients with ROS proto-oncogene 1 (ROS1) fusion–positive lung cancers, shown as the maximum percent improvement in the sum of longest diameters of identified target lesions compared with baseline, as assessed by BICR.

Fig 1. Waterfall plots of best response to entrectinib in patients with ROS proto-oncogene 1 (ROS1) fusion–positive lung cancers, shown as the maximum percent improvement in the sum of longest diameters of identified target lesions compared with baseline, as assessed by BICR.
  • Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F

  • J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.

2021-05-17

Fig 2. Mutational signature landscape in first responders and recovery workers exposed to the WTC disaster.

Fig 2. Mutational signature landscape in first responders and recovery workers exposed to the WTC disaster.
  • Maura F, Diamond B, Maclachlan KH, Derkach A, Yellapantula VD, Rustad EH, Hultcrantz M, Shah UA, Hong J, Landau HJ, Iacobuzio-Donahue CA, Papaemmanuil E, Irby S, Crowley L, Crane M, Webber MP, Goldfarb DG, Zeig-Owens R, Giricz O, Verma A, Prezant DJ, Dogan A, Shah SP, Zhang Y, Landgren O

  • Clin Cancer Res. 2021 Apr 1;27(7):2111-2118. doi: 10.1158/1078-0432.CCR-20-2245. Epub 2021 Jan 27.

2021-05-18

Fig 1. Terminal elongation-defective phenotypes for TS-EL mutants after L4 and late upshifts.

Fig 1. Terminal elongation-defective phenotypes for TS-EL mutants after L4 and late upshifts.
  • Jud MC, Lowry J, Padilla T, Clifford E, Yang Y, Fennell F, Miller AK, Hamill D, Harvey AM, Avila-Zavala M, Shao H, Nguyen Tran N, Bao Z, Bowerman B

  • G3 (Bethesda). 2021 Apr 15;11(4). pii: 6169531. doi: 10.1093/g3journal/jkab026.
Open Access button

2021-05-19

Figure 1: Mouse NK cell development and maturation.

Figure 1: Mouse NK cell development and maturation.
  • Mujal AM, Delconte RB, Sun JC

  • Annu Rev Immunol. 2021 Apr 26;39:417-447. doi: 10.1146/annurev-immunol-101819-074948.

2021-05-20

Fig. 1 RIF1 controls RT by reducing cell-to-cell variation in replication timing.

Fig. 1 RIF1 controls RT by reducing cell-to-cell variation in replication timing.
  • Klein KN, Zhao PA, Lyu X, Sasaki T, Bartlett DA, Singh AM, Tasan I, Zhang M, Watts LP, Hiraga SI, Natsume T, Zhou X, Baslan T, Leung D, Kanemaki MT, Donaldson AD, Zhao H, Dalton S, Corces VG, Gilbert DM

  • Science. 2021 Apr 23;372(6540):371-378. doi: 10.1126/science.aba5545. Epub 2021 Apr 22.

2021-05-21

Figure 3: Germline and somatic causes of neurodegeneration.

Figure 3: Germline and somatic causes of neurodegeneration.
  • Cox N, Pokrovskii M, Vicario R, Geissmann F

  • Annu Rev Immunol. 2021 Apr 26;39:313-344. doi: 10.1146/annurev-immunol-093019-111748.

2021-05-24

Fig 2. Reflectance confocal microscopy features seen across time in the study patients.

Fig 2. Reflectance confocal microscopy features seen across time in the study patients.
  • Navarrete-Dechent C, Cordova M, Liopyris K, Aleissa S, Rajadhyaksha M, Cohen G, Marghoob AA, Rossi AM, Barker CA

  • J Am Acad Dermatol. 2021 Jun;84(6):1575-1584. doi: 10.1016/j.jaad.2020.07.130. Epub 2020 Aug 20.

2021-05-25

Figure 1 Transcriptomic similarities across carcinomas with mucinous differentiation from different cancer types.

Figure 1 Transcriptomic similarities across carcinomas with mucinous differentiation from different cancer types.
  • Nguyen B, Sanchez-Vega F, Fong CJ, Chatila WK, Boroujeni AM, Pareja F, Weigelt B, Sotiriou C, Larsimont D, Reis-Filho JS, Desmedt C, Schultz N

  • Sci Rep. 2021 May 4;11(1):9478. doi: 10.1038/s41598-021-89099-2.
Open Access button

2021-05-26

Fig. 3: Repertoire of non-synonymous somatic mutations identified in metaplastic breast cancers.

Fig. 3: Repertoire of non-synonymous somatic mutations identified in metaplastic breast cancers.
  • da Silva EM, Selenica P, Vahdatinia M, Pareja F, Da Cruz Paula A, Ferrando L, Gazzo AM, Dopeso H, Ross DS, Bakhteri A, Riaz N, Chandarlapaty S, Razavi P, Norton L, Wen HY, Brogi E, Weigelt B, Zhang H, Reis-Filho JS

  • NPJ Breast Cancer. 2021 Apr 16;7(1):43. doi: 10.1038/s41523-021-00250-8.
Open Access button

2021-05-27

Fig. 3. Cryo-EM structure of the Nse5/Nse6 complex.

Fig. 3. Cryo-EM structure of the Nse5/Nse6 complex.
  • Yu Y, Li S, Ser Z, Sanyal T, Choi K, Wan B, Kuang H, Sali A, Kentsis A, Patel DJ, Zhao X

  • Proc Natl Acad Sci U S A. 2021 May 11;118(19). pii: 2026844118. doi: 10.1073/pnas.2026844118.

2021-05-28

Figure 1. Radiation treatment plan with isodose lines for a prescribed dose of 24 Gy in 1 fraction delivered to the L2 and L3 vertebral bodies.

Figure 1. Radiation treatment plan with isodose lines for a prescribed dose of 24 Gy in 1 fraction delivered to the L2 and L3 vertebral bodies.
  • Sarkar R, Schmitt AM, Yamada Y

  • Pract Radiat Oncol. 2021 May-Jun;11(3):e348-e350. doi: 10.1016/j.prro.2021.02.004.

2021-06-01

Graphical Abstract.

Graphical Abstract.
  • Xu K, Yin N, Peng M, Stamatiades EG, Chhangawala S, Shyu A, Li P, Zhang X, Do MH, Capistrano KJ, Chou C, Leslie CS, Li MO

  • Immunity. 2021 May 11;54(5):976-987.e7. doi: 10.1016/j.immuni.2021.04.008.

2021-06-02

Fig. 1. The autoantigenome from A549 cells identified by DS-affinity.

Fig. 1. The autoantigenome from A549 cells identified by DS-affinity.
  • Wang JY, Zhang W, Roehrl MW, Roehrl VB, Roehrl MH

  • J Autoimmun. 2021 Jun;120:102644. doi: 10.1016/j.jaut.2021.102644. Epub 2021 Apr 27.
Open Access button

2021-06-03

Fig 2. Activity of the eIF4A inhibitor [±]CR-1–31B against PDAC cells and organoids.

Fig 2. Activity of the eIF4A inhibitor [±]CR-1–31B against PDAC cells and organoids.
  • Singh K, Lin J, Lecomte N, Mohan P, Gokce A, Sanghvi VR, Jiang M, Grbovic-Huezo O, Burcul A, Stark SG, Romesser PB, Chang Q, Melchor JP, Beyer RK, Duggan M, Fukase Y, Yang G, Ouerfelli O, Viale A, de Stanchina E, Stamford AW, Meinke PT, Ratsch G, Leach SD, Ouyang Z, Wendel HG

  • Cancer Res. 2021 Feb 25. pii: 0008-5472.CAN-20-2929. doi: 10.1158/0008-5472.CAN-20-2929.
Open Access button

2021-06-04

Fig 3. Clinical and pathological associations of breast cancer mutation profile.

Fig 3. Clinical and pathological associations of breast cancer mutation profile.
  • Kingston B, Cutts RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, Swift C, Kilburn LS, Kernaghan S, Moretti L, Wilkinson K, Wardley AM, Macpherson IR, Baird RD, Roylance R, Reis-Filho JS, Hubank M, Faull I, Banks KC, Lanman RB, Garcia-Murillas I, Bliss JM, Ring A, Turner NC

  • Nat Commun. 2021 Apr 23;12(1):2423. doi: 10.1038/s41467-021-22605-2.
Open Access button

2021-06-07

Fig 2. Fig. 2: Melphalan mutational signatures.

Fig 2. Fig. 2: Melphalan mutational signatures.
  • Maura F, Weinhold N, Diamond B, Kazandjian D, Rasche L, Morgan G, Landgren O

  • Leukemia. 2021 May 19. pii: 10.1038/s41375-021-01293-3. doi: 10.1038/s41375-021-01293-3.

2021-06-08

Figure 4: Common network visualization.

Figure 4: Common network visualization.
  • Li Q, Pasquini L, Del Ferraro G, Gene M, Peck KK, Makse HA, Holodny AI

  • Sci Rep. 2021 May 19;11(1):10568. doi: 10.1038/s41598-021-90151-4.
Open Access button

2021-06-09

Figure 5. Proposed mechanism of increased CCND1 presentation after CDK4/6i treatment.

Figure 5. Proposed mechanism of increased CCND1 presentation after CDK4/6i treatment.
  • Charles A, Bourne CM, Korontsvit T, Aretz ZE, Mun SS, Dao T, Klatt MG, Scheinberg DA

  • OncoImmunology. 2021 Jan 1;10(1):1916243.
Open Access button

2021-06-10

Fig. 6: Cancer site specific odds ratios of most effective individual predictors in the hidden genome model applied to the PCAWG whole genome data.

Fig. 6: Cancer site specific odds ratios of most effective individual predictors in the hidden genome model applied to the PCAWG whole genome data.
  • Chakraborty S, Martin A, Guan Z, Begg CB, Shen R

  • Nat Commun. 2021 May 24;12(1):3051. doi: 10.1038/s41467-021-23094-z.
Open Access button

2021-06-11

Figure 2.  Lifetime Number of Colonoscopies and Life-Years Gained for a Cohort of 40-Year-Olds for Colonoscopy Screening Strategies.

Figure 2. Lifetime Number of Colonoscopies and Life-Years Gained for a Cohort of 40-Year-Olds for Colonoscopy Screening Strategies.
  • Knudsen AB, Rutter CM, Peterse EFP, Lietz AP, Seguin CL, Meester RGS, Perdue LA, Lin JS, Siegel RL, Doria-Rose VP, Feuer EJ, Zauber AG, Kuntz KM, Lansdorp-Vogelaar I

  • JAMA. 2021 May 18;325(19):1998-2011. doi: 10.1001/jama.2021.5746.
Open Access button

2021-06-14

Fig 1. Bispecific antibody platform has profound effects on the antitumor activity of bispecific antibody armed T cell immunotherapy. (A) BsAb structural platform.

Fig 1. Bispecific antibody platform has profound effects on the antitumor activity of bispecific antibody armed T cell immunotherapy. (A) BsAb structural platform.
  • Park JA, Santich BH, Xu H, Lum LG, Cheung NV

  • J Immunother Cancer. 2021 May;9(5). pii: jitc-2020-002222. doi: 10.1136/jitc-2020-002222.
Open Access button

2021-06-15

Fig 4. Resistance to lorlatinib with a ROS1 L2086F mutation and subsequent treatment with cabozantinib.

Fig 4. Resistance to lorlatinib with a ROS1 L2086F mutation and subsequent treatment with cabozantinib.
  • Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF

  • Clin Cancer Res. 2021 May 15;27(10):2899-2909. doi: 10.1158/1078-0432.CCR-21-0032. Epub 2021 Mar 8.

2021-06-16

Graphical abstract

Graphical abstract
  • Tamada M, Shi J, Bourdot KS, Supriyatno S, Palmquist KH, Gutierrez-Ruiz OL, Zallen JA

  • Dev Cell. 2021 Jun 7;56(11):1589-1602.e9. doi: 10.1016/j.devcel.2021.04.012. Epub 2021 Apr 30.

2021-06-17

Fig 1. Selected CAR T cell constructs currently in use or in development.

Fig 1. Selected CAR T cell constructs currently in use or in development.
  • Qualls D, Salles G

  • Hematol Oncol. 2021 Jun;39 Suppl 1:104-112. doi: 10.1002/hon.2844.
Open Access button

2021-06-18

Fig 2. Genome-wide LOH in TCGA-BLCA dataset and tumor tissue samples.

Fig 2. Genome-wide LOH in TCGA-BLCA dataset and tumor tissue samples.
  • Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury S

  • BMC Cancer. 2021 May 24;21(1):593. doi: 10.1186/s12885-021-08085-z.
Open Access button